BACKGROUND: Endomyocardial biopsy (EMBx) is considered the gold standard for rejection monitoring after heart transplantation; however, it is invasive and histologic interpretation has limitations. Sensitive blood biomarkers, including donor-derived cell-free DNA (dd-cfDNA), have emerged to decrease EMBx frequency. METHODS: We retrospectively reviewed data on 237 patients who underwent heart transplantation at our institution. Of these, 125 patients underwent monitoring using dd-cfDNA, combined with a fewer number of EMBx, and 112 patients underwent monitoring using EMBx only. We compared rates of rejection, graft dysfunction, and survival at 1 year. Comparatively, there were more EMBx defined antibody-mediated rejection (AMR) (5% vs 0.9%) and treated AMR (5% vs 2.7%) in the dd-cfDNA group. No significant differences were observed in graft dysfunction, presence of donor-specific antibodies, or survival at 1 year. CONCLUSIONS: In conclusion, a modern rejection surveillance protocol utilizing noninvasive testing is safe, led to significantly fewer EMBx, fewer treated rejection episodes, and no difference in survival at 1 year. More AMR episodes identified via dd-cfDNA could lead the way for more accurate diagnostic and treatment decisions.
No takes yet. Share an insight, caveat, or question.
Saeyeldin et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from JHLT Open